Immunovant, Inc.
No SEC Form 4 filings for $IMVT in the last 30 days.
Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, reported selling 3,115 shares of common stock on May 20, 2026, at prices ranging from $30.41 to $32.95 per share. These sales were not discretionary and were executed solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Melanie directly holds 244,973 shares of Immunovant common stock.
Immunovant, Inc.'s average 12-month stock price target has been increased from $40.29 to $43.08 by 12 analysts, implying a potential upside of 64% from its May 19 closing price. The consensus rating for the company remains a "Buy" among 13 analysts, with 9 recommending to buy, 4 to hold, and none to sell. Investors can find more detailed price target data and track analyst recommendations on the Forecasts tab and in the dedicated News Flow section.
U.S. stock futures were down on Thursday, with several companies experiencing significant drops in pre-market trading. Alto Neuroscience shares fell 13.6% after its Phase 2 clinical trial did not meet statistical significance. Immunovant Inc. also saw an 8.3% decline following the announcement of its Phase 3 study results.
